Small Cap Feast
Small Cap Feast – 07 March 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
DWF, a global legal business, expects to raise primary gross proceeds of approximately £75m. Due March
US Solar Fund, a newly-established investment company focused on investing in solar power assets mainly in the US, looking to raise $250m at $1. Expected 20 March
Techniplas –global producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient. FYDec17 rev $515m.
Diaceutics, a data analytics and implementation services company which services the global pharmaceutical industry, is looking to join AIM late March, offer TBC.
Petro Matad (MATD.L) 5.8p £38.4m
2019 four well drilling campaign: Heron, Gazelle, Red Deer (all Block XX) and a further exploration well in Block V, or appraisal of a Block XX discovery
Heron 1 well planned as first well of 2019 campaign, with spudding targeted for Q2 2019
More than 50% resource uplift at Heron Prospect to 25 MMbo from 16 MMbo following mapping of reprocessed 2D seismic
Gazelle high-graded to second Block XX well as new mapping shows it to be directly up dip of a Petro China discovery well on the same migration path
Red Deer Prospect location remains unchanged, targeting 48 MMbo of mean prospective recoverable resource
Heron, Gazelle and Red Deer environmental permits for drilling approved and CSR teams mobilised to well sites
Regulatory approval received for two-rig strategy for limited additional cost to allow for simultaneous drilling of prospects – negotiations with rig contractors nearing finalisation
Applications for Block IV and V PSCs being prepared for two-year extensions, with submission expected shortly
Ongoing analysis of Snow Leopard 1 well, Block V, has significantly enhanced the prospectivity of the Block and in particular the Raptor trend.
Strategic Minerals (SML.L) 1.7p £24m
Copper production is scheduled to recommence at the Leigh Creek Copper Mine’s Mountain of Light processing facility in April 2019, starting with the refurbishment and the trial reactivation of the existing processing plant and heap leach pads.
Engaged experienced operator PPM Global, who has previously worked at the MoL processing plant, to refurbish the existing MoL processing plant and to manage the trial restart of operations. PPM Global has mobilised and is currently on site.
Assay results from 250-hole shallow air core programme confirms the presence of residual copper in the existing heap leach pads
Reactivation of the existing heap leach pads fully covered under existing permits.
Feasibility study, for the commencement of full scale production from the Paltridge North and Rosmann East deposits, is well advanced with expected completion of resource estimation and economic evaluation scheduled for late second / early third quarter of 2019.
Block Energy (BLOE.L) 3.8p £9.9m
The exploration and production company focused on the Republic of Georgia, reported an increase in production rate at its 100%-held Norio field, where the Company is implementing a multi-well workover programme.
The oil production rate at Norio 44 has increased significantly over the past five days, rising daily to reach 21 bopd on the most recent day for which figures were available (6 March 2019). The Company’s initial forecast for the well was 15 bopd.
‘In parallel with the Norio recompletions the Company continues to progress its sidetracking operations at West Rustavi well 16a and expects to start drilling the 600m horizontal section within the next few days. Achieving the well’s base case initial production forecast of 325 bopd would be sufficient to move the Company well above its corporate production breakeven rate’.
Angle (AGL.L) 59.5p £85.4m
The “liquid biopsy company, announced that enrolment for its Parsortix FDA clinical study for metastatic breast cancer is now complete.
We are grateful to the four leading US cancer centres, the University of Texas MD Anderson Cancer Center, the University of Southern California Norris Cancer Center, the University of Rochester Wilmot Cancer Center, and the Northwestern University Robert H Lurie Cancer Center for their efforts in completing enrolment of all of the required 400 evaluable subjects.
Downstream analyses of the samples will now be completed by the centres and the evaluation of the results from the clinical study and the ongoing analytical studies will be completed with the aim of a submission to the FDA mid-year, as planned. The timing of FDA regulatory clearance is dependent on the FDA’s review and response to our submission. As we are following a de-novo process for the first potential FDA clearance1 of a system intended for harvesting cancer cells from patient blood for subsequent analysis, it is not possible to predict with certainty how long this process will take.”
Koovs (KOOV.L) 7.6p £27.05m
“The fashion-forward business focused on the young Indian e-commerce market, announced that its subsidiary Koovs Marketing Consulting Private Limited has signed an agreement with Future Lifestyle Fashions Limited (“FLFL”), part of Future Group, to develop, host and maintain an online platform for FLFL’s Brand Factory retail format.
Under the terms of the Technical Services Contract, Koovs will receive a one-off payment of $1.4m for the development of the Brand Factory online platform and an ongoing maintenance fee for a term of 24 months. The value of the maintenance fee will be equal to the cost incurred by Koovs in providing the maintenance of the Brand Factory online platform plus a management fee. Both the one-off payment and the maintenance fee are expected to be profitable for the Company.”
Ilika (IKA.L) 38p £38.3m
The pioneer in solid-state battery technology, announces the development and trial deployment of wireless sensors powered by Stereax®batteries for monitoring rail infrastructure. The project consortium consists of Ilika, Smart Component Technologies Ltd (SCT) and Network Rail.
In this 18-month project, self-powered sensors for monitoring key parameters affecting the performance of the railway infrastructure (load, temperature, shock) will be developed, deployed, tested and evaluated. The sensors will combine Ilika’s Stereax® solid-state battery technology and SCT’s novel ultra-low power sensor platform and will be wirelessly connected to Network Rail’s existing condition monitoring platform. The self-powered sensors will be maintenance free and will generate data 24/7, 365 days per year.
Quiz (QUIZ.L) 15.7p £19.6m
The omni-channel fashion brand, announces an update on trading during the period between 1 Jan 2019 to 28 Feb 2019 and its expectations for the financial year ended 31 March 2019.
The uncertain consumer spending backdrop has remained challenging for QUIZ. As a result, the Group has recorded a significant shortfall in sales compared to the Board’s prior expectations. Furthermore, there has been a requirement to apply higher than anticipated discounts to clear excess stock.
QUIZ has continued to increase sales online during the Period with Group online revenue increasing by 16.2%. However, this growth has been offset by an 11.1% decrease in revenue from the Group’s UK standalone stores and concessions. Consequently, Group revenue for QUIZ decreased by 1.7% in the Period against the comparable period last year.
New FYMar19 guidance, sales £129m, EBITDA c. 4.5m
Prophotonix (PPIX.L) 3.85p £3.5m
The United States Patent and Trademark Office has issued two US Patents for its COBRA Cure FX UV LED Curing Systems designed for use in UV curing applications in industrial printing, 3D printing and adhesives curing.
The first patent was awarded for the COBRA Cure FX series’ innovative replaceable window that facilitates the quick removal and cleaning or outright replacement of the window without the need for special tools (US10180248). In some applications, a build-up of material can occur on the exit window of the lamps that can reduce light output. In order to limit machine downtime to clean or replace the lamps, this invention allows for fast replacement of the window, minimizing any downtime for users.
A second patent was awarded for an innovative sensing network for early detection of issues that may occur during the normal operation of the lamp that could impact system performance (US10180249).
Serinus Energy (SENX.L) 11p £16.6m
The final assembly and testing of the Low Temperature Separation Unit (“LTS”) has been completed. The LTS was loaded and has left today from the Confind fabrication yard in Campina, Romania to the Moftinu plant site. The Moftinu site is approximately 550 km from the Confind facility.
Once on site the LTS will be reassembled and work will commence to install the unit in preparation for gas production.
The reassembly and installation of the Triethylene Glycol Unit is proceeding as planned.
Serinus is an international upstream oil and gas exploration and production company that owns and operates projects in Tunisia and Romania.
Sound Energy (SOU.L) 23.26p £249.3m
Continued positive discussions with Morocco’s Office National de l’Electricité et de l’Eau Potable (“ONEE”) and the Moroccan Minister of Energy in relation to a gas sales agreement (“GSA”), pursuant to which The Minister of Energy has confirmed his intention that the GSA covers all of the gas to be produced from the recently awarded Tendrara Production Concession, onshore Morocco. The GSA is a critical next step that Sound Energy and its partners require ahead of taking a Final Investment Decision on the development.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.